VENTURA-7 Research Study for Adults with MDD and Anhedonia

Principal Investigator

Joao L. De Quevedo, MD, PhD

Overview:

This study, led by Johnson and Johnson, aims to evaluate a new oral medication taken once daily as an adjunctive therapy for participants currently being treated for major depressive disorder (MDD) with moderate to severe anhedonia. This study focuses on individuals who have not responded adequately to their current treatment with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI).

Inclusion Criteria:

• Be 18 to 64 years of age.
• Meet DSM-5 diagnostic criteria for recurrent or single-episode MDD without psychotic features.
• Have symptoms of depression and anhedonia.
• Have had an inadequate response to at least 1 and up to 5 (inclusive) oral antidepressant treatments, including the current SSRI/SNRI, administered at an adequate dose for at least 6 weeks in the current depressive episode.
• Additional criteria will apply.

What you may be asked to do:

• Office visits.
• Completing surveys.
• Blood samples.
• Completing a medication diary.

What You May Get:

You may be compensated on a per-visit basis.

Location:

Interventional Psychiatry Clinic

7000 Fannin Street, Suite 1620

Houston, TX, 77030

Contact:

Email: [email protected]

Phone: (713) 486-2567

Take the study survey here 

ClinicalTrials.gov ID: NCT06514742 (https://clinicaltrials.gov/study/NCT06514742)